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Abstract
To evaluate the Dutch newborn screening (NBS) for medium-chain acyl-CoA
dehydrogenase (MCAD) deficiency since 2007, a nationwide retrospective, obser-
vational study was performed of clinical, laboratory and epidemiological parame-
ters of patients with MCAD deficiency born between 2007 and 2015. Severe
MCAD deficiency was defined by ACADM genotypes associated with clinical
ascertainment, or variant ACADM genotypes with a residual MCAD enzyme activ-
ity <10%. Mild MCAD deficiency was defined by variant ACADM genotypes with
a residual MCAD enzyme activity ≥10%. The prevalence of MCAD deficiency
was 1/8300 (95% CI: 1/7300-1/9600). Sensitivity of the Dutch NBS was 99% and
specificity ~100%, with a positive predictive value of 86%. Thirteen newborns with
MCAD deficiency suffered from neonatal symptoms, three of them died. Of the
189 identified neonates, 24% had mild MCAD deficiency. The acylcarnitine ratio
octanoylcarnitine (C8)/decanoylcarnitine (C10) was superior to C8 in discriminat-
ing between mild and severe cases and more stable in the first days of life. NBS for
MCAD deficiency has a high sensitivity, specificity, and positive predictive value.
In the absence of a golden standard to confirm the diagnosis, the combination of
acylcarnitine (ratios), molecular and enzymatic studies allows risk stratification. To
improve evaluation of NBS protocols and clinical guidelines, additional use of
acylcarnitine ratios and multivariate pattern-recognition software may be
reappraised in the Dutch situation. Prospective recording of NBS and follow-up
data is warranted covering the entire health care chain of preventive and curative
medicine.
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1 | INTRODUCTION
Medium-chain acyl-CoA dehydrogenase (MCAD, EC
1.3.8.7) facilitates the first step in the mitochondrial
β-oxidation of CoA-esters of medium-chain fatty acids.1
MCAD deficiency (#OMIM 201450) is the most common
inherited defect of mitochondrial fatty acid oxidation and is
potentially fatal. Acute symptoms and signs like encephalop-
athy and coma usually occur in infancy, biochemically asso-
ciated with hypoketotic hypoglycaemia.2 Outcomes are
excellent after early establishment of the diagnosis and con-
sequent management, which in the Netherlands includes the
advice on the avoidance of prolonged fasting3-6 and an
emergency regimen during intercurrent illness.
Testing for MCAD deficiency has been implemented in
population newborn bloodspot screening (NBS) programs in
many countries from the late 1990s.7 Concentrations of
(medium-chain length) acylcarnitines and their molar ratios
have been used as NBS parameters for MCAD deficiency.
Among countries, NBS protocols vary with respect to the
day of blood collection, analytical aspects, screening param-
eters, cut-off values, the use of post-analytical diagnostic
algorithms based on multivariate pattern recognition and
follow-up protocols to establish the definitive diagnosis.7-9
In the Netherlands, MCAD deficiency was introduced in the
national NBS program in 2007, after nationwide studies on
the natural history,10 the epidemiology,11 a prospective pilot
NBS study in the northern part of the country12 and an eco-
nomic evaluation.13
The fundamental purpose of population NBS (for MCAD
deficiency) is to rapidly diagnose newborns in order to pre-
vent or reduce irreversible morbidity and mortality by early
treatment. It was demonstrated that our national NBS pro-
gram for MCAD deficiency identifies more patients,11,14
with previously unreported ACADM genotypes, than histori-
cally recognized through clinical ascertainment.14,15 Case
definition of MCAD deficiency has, therefore, become more
difficult.16-18 Also, it is recognized that some MCAD defi-
cient patients display acute (fatal) symptoms, before NBS
results have become available, or even before blood samples
have been taken.16,19-22
To evaluate the Dutch population NBS for MCAD defi-
ciency since 2007, we performed a nationwide retrospective,
observational study of clinical, laboratory and epidemiologi-
cal parameters.
2 | METHODS
2.1 | Ethics approval
For this retrospective cohort study, the Medical Ethical
Committee (METc) of the University Medical Center
Groningen provided a waiver indicating that the Medical
Research Involving Human Subjects Act was not applicable
and official study approval by the METc was not required
(METc 2015/540).
This article does not contain any studies with animal sub-
jects performed by the any of the authors.
2.2 | Informed consent
All procedures followed were in accordance with the ethical
standards of the responsible committee on human experi-
mentation (institutional and national) and with the Helsinki
Declaration of 1975, last revision in 2013 (5).
For the Dutch NBS, written parental informed consent is
not required, as described in detail elsewhere.
The retrospective study is exempted from formal
IRB/Ethics board review, because the Medical Research
Involving Human Subjects Act is not applicable. Under
these circumstances and when data are used anonymously,
individual subject's informed consent is not required, as per
institutional and national rules.
2.3 | Dutch population NBS protocol for
MCAD deficiency and follow-up
The Dutch NBS is coordinated by the Centre for Population
Screening of the National Institute for Public Health and the
Environment (RIVM). Filter paper dried blood spots (DBS)
are collected between 72 and 168 hours after birth (managed
in 98.8% of the newborns) and sent to one of the five
national screening laboratories for analysis. The national lab-
oratories perform quality monitoring quarterly. In the Neth-
erlands participation in the population NBS program is
~99.5%.23
For MCAD deficiency, the primary screening marker, on
which referral is solely based, is the DBS concentration of
octanoylcarnitine (C8 cut off ≥0.5 μmol/L), derived from a
conservative estimate based on literature24,25 and adapted
after a prospective pilot screening in the northern part of the
Netherlands.10 The ratio between C8 and decanoylcarnitine
(C8/C10) (cut off >5.0) is reported as a secondary marker,
whereas C2, C6, and C10:1 are reported as tertiary markers.
However, these markers do not influence the decision-taking
progress (www.rivm.nl). The Dutch NBS algorithm for
MCAD deficiency has not changed during this study.
Approximately 98% of the newborns with abnormal
screening results are reported within 1 week after birth to the
general practitioner (GP) and the nearest metabolic center.
After the immediate referral by the GP, the newborns are
seen within 24 hours for clinical and laboratory follow-up in
the metabolic center. Here diagnosis is established according
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to the Dutch standard of care protocol for MCAD defi-
ciency26 by a combination of:
• Increased medium-chain (C6 to C12) plasma
acylcarnitines, especially C8, and relevant ratio's (such as
C8/C10 and C8/C2).
• Increased urinary organic acid excretions, particularly
hydroxy acids, dicarboxylic acids and glycine derivatives
of hexanoic-, suberic-, and phenylpropionic acid.
• MCAD enzyme activity, determined in leucocytes or lym-
phocytes isolated from freshly collected blood, with an
HPLC-based assay using 3-phenylpropionyl-CoA as a
substrate, as published previously.27-29 Assays are per-
formed in duplo (interassay variation <10%). Residual
enzyme activities are expressed as percentage of healthy
controls.
• ACADM gene mutation-analysis.
In the Netherlands, the costs of the above-mentioned con-
firmatory follow-up testing are covered by health insurance
companies.
2.4 | Cohort
Included were all Dutch children with an established diagno-
sis of MCAD deficiency born in 2007 up to and including
2015. Data were retrieved from the RIVM, the Dutch meta-
bolic centers, and their collaborating laboratories. The Dutch
Diagnosis Registration Metabolic Diseases Database (www.
ddrmd.nl), a national registry for positive NBS screening
results of patients with confirmed diagnosis of an IEM, and
the Dutch Pediatric Surveillance Unit30 served a control for
possible false-negatives. Acylcarnitine concentrations from
1000 healthy newborns were retrieved as a reference cohort
from the RIVM.
2.5 | Data analysis
Based on previously published methods14 severe MCAD
deficiency was defined by ACADM genotypes associated
with clinical ascertainment, or ACADM genotypes not
associated with clinical ascertainment (variant ACADM
genotypes) with a residual MCAD enzyme activity
<10%. Mild MCAD deficiency was defined by variant
ACADM genotypes with a residual MCAD enzyme activ-
ity ≥10%.
Prevalence (P) was calculated by dividing the number of
patients with MCAD deficiency diagnosed between 2007
and 2015 by the total number of live births (N). The total
number of live births was acquired from the Dutch Central
Bureau for Statistics (ww.cbs.nl). The confidence interval
(CI) was calculated as:
95%CI =P1:96× ð P× 1−Pð Þ=NÞð Þ1=2
The z-scores of individual NBS screenings parameters
(μ) were established with the mean (X) and SD (σ) derived
from the reference population using:
Z =
X−μ
σ
Data analysis and visualization was performed using
IBM SPSS Statistics for Windows, (IBM Corp. Released
2016. Version 24.0. Armonk, New York), GraphPad Prism
software (GraphPad Software Inc. Released 2016. Version
7.02. San Diego, California) and R (Version 3.4.0, Vienna,
Austria). The not normally distributed data was described
with medians and interquartile ranges (IQR) and analyzed
using Mann-Whitney U or Kruskal-Wallis test, followed by
Dunn's multiple comparison test. The sensitivity and speci-
ficity of the screening parameters were calculated and illus-
trated by Receiver Operating Characteristic (ROC) curves.
The areas under the ROC curves (AUCs of ROCs) were ana-
lyzed using Delong test and the 95% confidence interval was
generated (CI 95%). Optimal cut-offs were established using
R package “OptimalCutpoints” version 1.1-3.31 Minimum
distance to the top left corner was calculated using:
d=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1−sensitivityð Þ2 + 1−specificityð Þ2
q
The Youden index was established using:
J = sensitivity + specificityð Þ−1
Differences were considered significant when P < .05.
3 | RESULTS
3.1 | Epidemiology
A total of 1 614 278 DBS were analyzed, 219 subjects were
referred after positive screening results and 189 eventually
diagnosed with MCAD deficiency. Two false-negatives
cases were identified, and three patients were diagnosed
post-mortally. The sensitivity of the Dutch NBS program for
MCAD deficiency was 99% and the specificity ~100%, with
a positive predictive value (PPV) of 86%. With 1 608 333
live births, the prevalence of MCAD deficiency was 1/8300
(95% CI: 1/7300-1/9600) (Table 1).
Three c.985A > G ACADM homozygotes died on the
second (n = 1) and third (n = 2) day of life, before DBS col-
lection. Hence, these children could not be identified by the
NBS program. Additionally, eight patients identified by the
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NBS, already suffered from symptoms during the neonatal
period. ACADM molecular studies revealed c.985A>G
homozygosity (n = 5) and compound heterozygosity for the
c.789A>G mutation (with c.985A>G [n = 1] and
c.233 T>C [n = 1]) in these cases. From one patient with
neonatal symptoms, in whom ACADM gene mutation-
analysis data is lacking, residual enzyme activity was 0%.
Five of these patients with neonatal symptoms had been
admitted to the hospital before NBS test results became
available, three with documented hypoglycaemia.
In eight newborns frequent feeds were advised from birth
because of a family history of MCAD deficiency. Interest-
ingly, two of these patients, both compound heterozygotes
for the variant c.985A>G and c.199T>C ACADM muta-
tions, were not detected by the NBS program (sampling days
not documented). Their C8 concentrations were 0.22 μmol/L
and 0.35 μmol/L (respectively 10 and 17 z-scores above the
median). The C8/C10 ratios were 2.4 and 2.3 (respectively
3.4 and 3.6 z-scores above the median), whereas the C8/C2
ratio was 0.3 in one of the cases (23 z-scores above the
median). In the second case, the C8/C2 ratio was missing.
The residual enzyme activities were 42% and 48%, respec-
tively. Therefore, these two false-negatives were categorized
as mild MCAD deficiency.
3.2 | ACADM genotypes and residual enzyme
activity
Data on ACADM gene mutations analysis were available for
88% (167/191) of the screened patients. The c.985A>G
ACADM allele frequency was 75% (252/334); 58% (97/167)
of the patients were homozygous for this classic mutation,
35% (58/167) were compound heterozygotes. Five previ-
ously unreported ACADM mutations were identified;
c.1229T>C, c.614C>T, c.653C>G, c.745G>A, appearing
in combination with c.985A>G, and c.794_803delinsTTTAAA
combined with c.600-18G>A. None of these patients were
documented to have neonatal symptoms.
Combined data on both residual MCAD enzyme activi-
ties and ACADM genotypes could be retrieved from 83%
(159/191) of the screened patients (Table SS1). In total, 24%
(38/159) were categorized as mild MCAD deficiency, of
whom 61% (23/38) had residual MCAD enzyme activities
≥30%. Nine of the patients with variant ACADM genotypes
were categorized as severe MCAD deficiency, as they dis-
played residual MCAD enzyme activities <10%. Three indi-
viduals carrying the c.799G>A mutation33,34 displayed
residual MCAD enzyme activities around 10% (Table S1).
3.3 | Population NBS screening parameters
Table 2 presents the population NBS acylcarnitine levels for
the Dutch MCAD deficiency cohort 2007-2015. The median
C8 concentration, C8/C10 and C8/C2 ratio all statistically
differed (Mann-Whitney U, P < .05) between true-positives
and the control cohort (Table 2).
Comparing the AUC of ROC (CI 95%) of C8 (0.94
[0.90-0.98]), C8/C10 [0 .79 (0.67-0.91]) and C8/C2 (0.92
[0.87-0.96]) for MCAD deficiency patients and NBS false-
positives, showed that C8 and C8/C2 were more accurate at
predicting MCAD deficiency than C8/C10 (Delong,
P < .05) (Figure 1A). Interestingly, comparing the AUC of
TABLE 1 Epidemiology of MCAD deficiency in the Netherlands
MCAD deficiency Frequencies (95% CI)
ACADM mutation carrier
frequency(a)
1/55 (1/46-1/68)
Expected prevalence(a) 1/12100 (1/8450-1/18500)
Observed prevalence 1985-1999(b) 1/27400 (1/23000-1/33900)
Observed prevalence NBS
2007-2010(c)
1 8750 (1/7210-1/11130)
Live births 2007-2015(d) 1 608 333
Expected MCAD deficient patients
2007-2015(a)
183 (144-223)
Positive screenings NBS
2007-2015
219
MCAD deficiency patients
2007-2015
194
Observed Prevalence 2007-2015 1/8300 (1/7300-1/9600)
Legend: (a) according to Reference 32 (b) according to Reference 11
(c) according to Reference 14 (d) CBS, 2016.
TABLE 2 Population NBS parameters for MCAD deficiency
Group (n) C8* C8/C10 C8/C2*
TP 2.74 12.3 0.20
(n = 189) (1.57-4.75) (9.0-13.9) (0.09-0.31)
Severe 3.38 13.1 0.24
(n = 121) (1.9-5.4) (11.6-14.3) (0.16-0.34)
Mild 1.12 3.10 0.05
(n = 38) (0.72-1.81) (2.7-3.7) (0.03-0.08)
FP 0.61 2.3 0.03
(n = 30) (0.55-0.8) (0.7-7.7) (0.03-0.04)
FN 0.29 2.35 0.03
(n = 2) (0.22-0.35) (2.3-2.4) 0.03
Control 0.04 0.8 0.002
(n = 1000) (0.03-0.05) (0.7-1.0) (0.002-0.003)
Legend: median values (IQR) displayed for population NBS parameters for
MCAD deficiency in the Dutch NBS cohort 2007-2015. TP, true-positives; FP,
false-positives. *no significant difference was found between the value of TP
and FP (Kruskal-Wallis, P > .05). The severe and mild group consist of the
patients from which the combined data on both residual MCAD enzyme
activities and ACADM genotypes were available (n = 159).
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ROC (CI 95%) of C8, C8/C10 and C8/C2 between severe
and mild MCAD deficient patients, that is, 0.87 (0.80-0.93),
0.98 (0.94-1.00) and 0.94 (0.90-0.99), respectively, both
ratios were found to predicted disease severity more accu-
rately compared to C8 (Delong, P < .05) (Figure 1B).
Application of C8, C8/C10 and C8/C2 as primary screen-
ing markers to solely identify severe MCAD deficiency (cut-
off values maximizing sensitivity established at; C8:
0.77 μmol/L [100% sensitivity and 97% specificity];
C8/C10: 3.2 [100% sensitivity and 97 specificity] and
C8/C2: 0.038 [100% sensitivity and 97% specificity]) would
have resulted in the elimination of 80% of the false positives
and 58% (22/39) of the mild MCAD deficiency cases. These
mild MCAD deficiency subjects would have represented
residual MCAD enzyme activities ranging between 11% and
65% and most would have carried the ACADM
c.985A>G/c.199T>C genotype (n = 10).
The median age at NBS blood sampling of the MCAD
deficiency patients (n = 183; missing data in 6 cases) was
4 days (range: 3-6). Median (IQR) concentrations of C8 are
highest when NBS was performed earlier; 5.9 (3.1-9.2), 3.2
(1.8-4.8), 1.8 (1.3-3.3) and 1.5 (1.1-2.4) μmol/L on day
three, four, five and six, respectively (Kruskal Wallis,
P < .05) (Figure 2A). Median (IQR) C8/C2-ratios also
declined from 0.30 (0.21-0.39) on day three to 0.16
(0.11-0.21) on day six, albeit not significantly (Kruskal Wal-
lis, P > .05) (Figure 2B). The median (IQR) C8/C10-ratio
ranged between 12.55 (11.23-15.00, on day three) to
12.35 (10.73-12.88, on day 5) (Kruskal Wallis, P > .05)
(Figure 2C).
4 | DISCUSSION
The present study is a nationwide retrospective, observa-
tional study of clinical, laboratory and epidemiological
parameters of population NBS for MCAD deficiency in the
Netherlands with a high acceptance rate. During nearly a
decade in which 1.6 million DBS were studied, we identified
194 patients of whom most were characterized at both an
enzymatic and molecular level.
The sensitivity of the Dutch NBS program was 99% and
the specificity ~100%, with a PPV of 86%. This high-
performance rate of the Dutch NBS is partly explained by
the Dutch follow-up protocol to confirm the diagnosis. The
prevalence of MCAD deficiency is 1/8300 (CI 95%:
1/7300-1/9600), in agreement with the estimate based on the
ACADM c.985A>G carrier frequency in the general popula-
tion and the assumption of a 94% allele frequency for this
common mutation in clinically ascertained cases.14,32
Although the Dutch NBS program is thus very suitable to
identify MCAD deficiency, it can be discussed whether the
current follow-up approach only identifies those neonates
prone to morbidity or mortality due to the disorder.
To date, there is no gold standard to confirm the diagno-
sis of MCAD deficiency. The Dutch follow-up protocol
allows retrospective risk assessment based on clinical and
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FIGURE 1 ROC curves of the population NBS markers for differentiating (A) MCAD deficiency patients from false-positives and
(B) between severe and mild MCAD deficiency. Legend: The true positive rate (sensitivity) and false positive rate of the C8 concentration (μmol/L),
C8/C10 ratio and C8/C2 ratio between (A) screened MCAD deficiency patients (TP + FN, n = 1191) and false-positives (n = 30). The gray line
represents C8, the black dashed line represents C8/C10, and the black line represents C8/C2. the points represent the optimal thresholds. Optimal
thresholds were established at C8 = 1.35 μmol/L (sensitivity: 97%, specificity: 80%, d = 0.20 J = 0.77), C8/C10 = 9.8 (sensitivity 83%, specificity:
73%, d = 0.32, J = 0.56) and C8/C2 = 0.094 (sensitivity: 87%, specificity: 88%, d = 0.18, J = 0.75). (B) between severe MCAD deficiency
(n = 121) and mild MCAD deficiency (n = 38) patients. Optimal thresholds were established at C8 = 1.76 μmol/L (sensitivity: 76%, specificity:
80%, d = 0.31, J = 0.56), C8/C10 = 8.4 (sensitivity: 95%, specificity: 95%, d = 0.071, J = 0.90) and C8/C2 = 0.095 (sensitivity: 86%, specificity:
90%, d = 0.17, J = 0.76)
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multiple laboratory parameters. ACADM gene sequencing
and identification of bi-allelic mutations is frequently used
for confirmatory testing after initial abnormal NBS results
for MCAD deficiency. However, already before the intro-
duction of NBS programs, MCAD deficiency had a poor
genotype-phenotype correlation.10,15,35,36 Some ACADM
genotypes (such as c.985A > G homozygosity) can cause a
clinical phenotype. For positively screened newborns with
variant ACADM genotypes, both C8/C10 and in vitro studied
residual MCAD enzyme activity can be of additional value
for risk prediction.14,37 The c.985A > G ACADM homozy-
gotes have residual activities <1% and ACADM genotypes
resulting in residual activities <10% are observed in patients
with neonatal clinical presentations, hypoglycaemias and
more frequent preventive hospital admissions.14 Further-
more, heterozygous carriers of the c.985A>G mutation have
residual enzyme activities >22%.37-39
In this study, we found that nearly a quarter of the neo-
nates identified by the Dutch NBS program have mild
MCAD deficiency. If mild MCAD deficiency cases would
be excluded, the prevalence would still be in line with the
estimate based on the c.985A>G ACADM carrier frequency
in our country. It can be questioned whether mild MCAD
deficiency cases, such as compound heterozygotes for the
c.985A>G and c.199T>C ACADM mutations, realistically
carry clinical risks or only demonstrate a biochemical varia-
tion causing unnecessary anxiety, medical interventions, and
follow-up.48,49 Long-term clinical follow-up studies are
warranted to assess the clinical consequences of mild
MCAD deficiency.
This study demonstrates that -for those countries where
enzyme activity is not measured routinely- the C8/C10 ratio
is a powerful marker for early discrimination between severe
and mild MCAD deficiency cases (Figure 1B). Multivariate
pattern-recognition software (including acylcarnitine ratios),
such as from the Collaborative Laboratory Integrated
Reports (CLIR), could be used alternatively to differentiate
between severe and mild MCAD deficiency cases40 and cir-
cumvent the definition of an exact-cut off.33
This study demonstrated that C8/C10 is more stable in
the first days of life than C8 in subjects with MCAD defi-
ciency. It has been demonstrated that C8 concentrations do
not vary between 4 and 6 days of life in normal, healthy neo-
nates.41 Earlier studies reported that the C8/C10 ratio was
neither influenced by metabolic stress nor by nutritional
state,42,43 in contrast to the C8 concentration.8,44,45 In vari-
ous NBS protocols across the world C8/C10 is implemented
as a second parameter.8
Despite the high clinical awareness in our country and
early detection by NBS, this study identified at least three
patients who died before DBS could be obtained. We
recently reported that the C8 concentration and C8/C10 ratio
in cord-blood from MCAD-deficient patients are already
abnormal and the C8/C10 ratio is already remarkably stable
during the first 2 days of life.21,22 This indicates that earlier
screening using C8/C10 ratio may enable rapid diagnosis of
MCAD deficiency. However, changing the timing for one
disorder would affect (the timing of) the entire health care
chain of a national NBS program, including cut-off values
for the remaining disorders.
Some methodological issues of this study should be
addressed. Several factors are reported to influence
acylcarnitine profiles, such as (very) low birthweight and
prematurity.25,45-47 These factors were not systematically
collected in this study, but deserve future attention using
multivariate pattern-recognition software, including age in
hours at sampling. Second, laboratory follow-up has differed
among the patients. The enzyme analysis is performed in
leukocytes or lymphocytes, even though the latter seems
preferable.14,37 Recently a national central facility for inte-
grated and continuous documentation of the population NBS
program was implemented (NEORAH). If follow-up data
would be incorporated, this holds the potential of future
(international) data sharing, covering the entire health care
chain of preventive and curative medicine.
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FIGURE 2 NBS screening parameters according to the day at which the NBS bloodspot was obtained in screened MCAD deficiency patients
for (A) C8, (B) C8/C10 and (C) C8/C2. Legend: the values of the various screening markers, (A) C8 concentration (μmol/L), (B) C8/C10 ratio
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